Anti h3k79me2

Manufactured by Abcam

Sourced in United States

Anti-H3K79me2 is a research-use-only product that detects the dimethylation of histone H3 at lysine 79. It can be used in various applications to study this epigenetic modification.

Automatically generated - may contain errors

Lab products found in correlation

Anti histone h3, by Abcam (2 mentions) Anti h3k27me3, by Abcam (2 mentions) Anti dot1l, by Cell Signaling Technology (2 mentions) Anti gapdh, by Cell Signaling Technology (2 mentions) Anti β actin, by Cell Signaling Technology (2 mentions) Trizol, by Thermo Fisher Scientific (2 mentions) Anti snrnp70, by Abcam (1 mentions) Anti kdm7a, by GeneTex (1 mentions) Anti h3k4me3, by Merck Group (1 mentions) Anti h3k27me2, by Cell Signaling Technology (1 mentions) Anti akt, by Cell Signaling Technology (1 mentions) Anti cleaved caspase 3, by Cell Signaling Technology (1 mentions) Anti tubulin, by Abcam (1 mentions) Anti h3k4me2, by Merck Group (1 mentions) Anti h3k4me1, by Merck Group (1 mentions) Anti hnrnp a1, by Merck Group (1 mentions) Anti h3k27me1, by Abcam (1 mentions) Anti kdm4a, by Abcam (1 mentions) Anti kdm5a, by Abcam (1 mentions) Anti kdm5c, by Abcam (1 mentions)

5 protocols using anti h3k79me2

Histone Modification Analysis Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

EPZ-5676 was provided by Epizyme, and DMSO was purchased from Sigma (cat. no. D2438). Cells were dissociated using TrypLE Express Enzyme (Thermo Fisher Scientific, cat. no. 12604021). Primary antibodies used for histone blots were as follows: anti-H3K79me2 (Abcam; ab3594), anti-Histone H3 (Abcam; ab1791). Fluorophore-conjugated secondary antibody IRDye 680RD Donkey anti-Rabbit IgG (Licor, 92568073) was used for histone blots. Primary antibodies used for Western blots were as follows: anti-DOT1L (Cell Signaling; 77087S), anti-cMyc (Cell Signaling; 5605S), anti-SOX2 (Cell Signaling; 3579S), anti-H3K79me2 (Abcam; ab3594), anti-GAPDH (Cell Signaling; 2118S), and anti–β-actin (Cell Signaling; 4970S). HRP-conjugated anti-rabbit IgG (W4011) and anti-mouse IgG (W4021) were purchased from Promega.

Kurani H., Razavipour S.F., Harikumar K.B., Dunworth M., Ewald A.J., Nasir A., Pearson G., Van Booven D., Zhou Z., Azzam D., Wahlestedt C, & Slingerland J. (2022). DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer. Clinical Cancer Research, 28(9), 1948-1965.

+ Open protocol

+ Expand

Antibody Validation for Epigenetic Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies were purchased from the following companies: anti‐H3K27me1, anti‐H3K27me3, anti‐H3K79me1, anti‐H3K79me2, anti‐histone H3, anti‐hnRNP I, anti‐KDM4A, anti‐KDM5A, anti‐KDM5C, anti‐snRNP70, anti‐tubulin, and anti‐U2AF2 from Abcam (Cambridge, MA, USA); anti‐hnRNP A2/B1 from Acris (San Diego, CA, USA); anti‐SR protein‐specific kinases (SRPK)1 and anti‐SRPK2 from BD Biosciences (San Diego, CA, USA); anti‐AKT, anti‐H3K27me2, anti‐protein phosphatase‐1 (PP1), anti‐phospho‐PP1 at Thr320, anti‐phospho‐AKT at Ser473, and anti‐cleaved‐CASPASE‐3 from Cell Signaling Technology (Billerica, MA, USA); anti‐H3K4me1, anti‐H3K4me2, anti‐H3K4me3, and anti‐H3K36me3 from Millipore; anti‐pro‐CASPASE‐3 and anti‐KDM7A from GeneTex (SanAntonio, TX, USA); anti‐hnRNP C1/C2, anti‐BAX, and anti‐BCL2L1 from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti‐hnRNP A1 from Sigma; and anti‐SRSF1 and anti‐SRSF3 from Zymed (San Francisco, CA, USA).

Lee C., Chang W., Chang Y., Yang J., Chang C., Hsu K., Chen Y., Liu T., Chen Y., Lin S., Wu Y, & Chang J. (2019). Alternative splicing in human cancer cells is modulated by the amiloride derivative 3,5‐diamino‐6‐chloro‐N‐(N‐(2,6‐dichlorobenzoyl)carbamimidoyl)pyrazine‐2‐carboxide. Molecular Oncology, 13(8), 1744-1762.

+ Open protocol

+ Expand

Western Blot Analysis of Epigenetic Regulators

Check if the same lab product or an alternative is used in the 5 most similar protocols

5×10⁴ PBS washed cells were lysed in 50 μL of 1× loading buffer supplemented with 10 mM DTT and denatured for 10 min at 95°C. Samples were loaded (20 μL per lane) onto either 10% Bis-Tris or Tris-Acetate gels (ThermoFisher), proteins were separated by electrophoresis for 2 hr then transferred onto nitrocellulose membrane using semi-dry transfer (ThermoFisher). The membranes were blocked in 5% dry milk for 30 min and incubated overnight with anti-Menin (Bethyl), anti-DOT1L (Cell Signaling), anti-H3K79me2 (Abcam) or anti-GAPDH (Cell Signaling) antibody. The next day membranes were washed in TBST and developed using a secondary rabbit anti-HRP (Cell Signaling) and chemiluminescence kit (Pierce).

Krivtsov A.V., Evans K., Gadrey J.Y., Eschle B.K., Hatton C., Uckelmann H.J., Ross K.N., Perner F., Olsen S.N., Pritchard T., McDermott L., Jones C.D., Jing D., Braytee A., Chacon D., Earley E., McKeever B.M., Claremon D., Gifford A.J., Lee H.J., Teicher B.A., Pimanda J.E., Beck D., Perry J.A., Smith M.A., McGeehan G.M., Lock R.B, & Armstrong S.A. (2019). A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer cell, 36(6), 660-673.e11.

+ Open protocol

+ Expand

Isolation and Analysis of Intestinal Epithelial Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

IECs were isolated from murine samples by shaking intestinal tissue in 1 mM EDTA/1 mM DTT and 5% FCS at 37°C for 10 min, resulting in 80–90% EpCAM⁺ IEC purity. RNA was isolated from cells using TRIzol (ThermoFisher Scientific) reagent then subjected to reverse transcription with AMV reverse transcriptase (Promega). Real-time PCR was performed using SYBR green chemistry (Applied Biosystems). Reactions were run on a real-time PCR system (StepOne Plus Real-Time PCR System; Applied Biosystems) Specific primers are listed in Supplementary Table S2. For Western blotting, IECs were lysed in a modified RIPA buffer (ThermoFisher Scientific) and lysates were subjected to immunoblot analysis. Blots were probed with rabbit anti-H3K79me2, H3K79me3, H3K4me2, H3K4me3, H3K27me3 (Abcam), total H3 (Cell Signaling), and GAPDH (Invitrogen).

Sun D., Wang W., Guo F., Pitter M.R., Du W., Wei S., Grove S., Vatan L., Chen Y., Kryczek I., Fearon E.R., Fang J.Y, & Zou W. (2022). DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway. Oncoimmunology, 11(1), 2052640.

+ Open protocol

+ Expand

Western Blot Analysis of Histone Modifications

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells (1 × 10⁶) were lysed in 100 µL of 2× sodium dodecyl sulphate (SDS) sample buffer containing radioimmunoprecipitation assay buffer, phenylmethylsulfonyl fluoride and protease inhibitors; sonicated for 20 seconds; and then boiled at 98°C for 8 minutes. Equal amounts of protein were then separated by SDS‐polyacrylamide gel electrophoresis and electrotransferred to polyvinylidene difluoride membranes (Millipore, Burlington, MA). After blocked with 5% not‐fat milk, the membranes were then incubated with the following primary antibodies at 4°C overnight: anti‐SETD2 (Cat#69836; Abcam, Cambridge, UK; Cat#LS‐C332416; LSBio, Seattle, WA), anti‐H3 (Cat#ab1791; Abcam), anti‐H3K36me3 (Cat#ab9050; Abcam), anti‐H3K27me3 (Cat#ab6002; Abcam), anti‐H3K79me2 (Cat#ab3594; Abcam), anti‐TBP (Cat#66166‐1‐lg; Proteintech, Chicago, IL), anti‐H3K9me3 (Cat#A2360; ABclonal, Boston, MA) and anti‐β‐actin (Cat#3700; Cell Signaling Technology, Danvers, MA).

Sheng Y., Ji Z., Zhao H., Wang J., Cheng C., Xu W., Wang X., He Y., Liu K., Li L., Voeltzel T., Maguer‐Satta V., Gao W, & Zhu H.H. (2019). Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells. Cell Proliferation, 52(4), e12611.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!